ArticleImmunity2018
Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
Open access · hybridAbstract read
In one paragraph
Article in Immunity, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.4field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 84 citations in OpenAlex.
- Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.Frontiers in immunology · 2024Trial
- Trial
- The 2026 Bundibugyo virus disease outbreak in the Democratic Republic of the Congo: Virology, epidemiology, continental response, and research priorities.Infectious medicine · 2026Review
- Bundibugyo Virus Disease: Diagnostics and Medical Countermeasures for a Neglected Ebolavirus.Viruses · 2026Review
- Mapping the global evidence base of bundibugyo ebolavirus disease: a systematic scoping review of research gaps and preparedness priorities.BMC infectious diseases · 2026Article
- A broadly-neutralizing antibody against Orthoebolavirus glycoprotein that potentiates the breadth and neutralization of other antibodies.Npj viruses · 2026Article
- A highly potent nanobody-based bispecific therapeutic provides broad-spectrum protection against ebolavirus.Nature communications · 2026Article
- Article
- Rational design of next-generation filovirus vaccines combining glycoprotein stabilization and nanoparticle display with glycan modification.Nature communications · 2025Article
- HIV broadly neutralizing antibody precursors to the Apex epitope induced in nonhuman primates.Science immunology · 2025Article
- Rational design of next-generation filovirus vaccines through glycoprotein stabilization, nanoparticle display, and glycan modification.bioRxiv : the preprint server for biology · 2025Article
- A pan-orthoebolavirus neutralizing antibody encoded by mRNA effectively prevents virus infection.Emerging microbes & infections · 2024Article
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Antibodies targeting the glycan cap of Ebola virus glycoprotein are potent inducers of the complement systemCommunications biology · 2024Article
- A Pan-Ebolavirus Monoclonal Antibody Cocktail Provides Protection Against Ebola and Sudan Viruses.The Journal of infectious diseases · 2023Article
- Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin.Cell reports · 2023Article
- Structural and mechanistic basis of neutralization by a pan-hantavirus protective antibody.Science translational medicine · 2023Article
- Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes.Cell reports · 2023Article
- Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin.Pharmacology & therapeutics · 2022Review
- Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region.PLoS pathogens · 2022Article
Corrections and comments
- Commented on by
Authors and funding
32 authors at 11 institutions in 2 countries.
Pavlo GilchukVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Natalia KuzminaDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.
Philipp A IlinykhDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.
Kai HuangDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA.
Bronwyn M GunnRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Aubrey BryanIntegral Molecular, Inc., Philadelphia, PA 19104, USA.
Edgar DavidsonIntegral Molecular, Inc., Philadelphia, PA 19104, USA.
Benjamin J DoranzIntegral Molecular, Inc., Philadelphia, PA 19104, USA.
Hannah L TurnerDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Marnie L FuscoThe Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Matthew S BrambleDepartment of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Genetic Medicine Research, Children's Research Institute, Children's National Medical Center, Washington, DC 20010, USA.
Nicole A HoffDepartment of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Elad BinshteinDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Nurgun KoseVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Andrew I FlyakDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Robin FlinkoDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Chiara OrlandiDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Robert CarnahanVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Erica H ParrishVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Alexander M SevyChemical and Physical Biology Program, Vanderbilt University, Nashville, TN 37232, USA.
Robin G BombardiVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Prashant K SinghDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Patrick MukadiInstitut Nationale de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
Jean Jacques Muyembe-TamfumInstitut Nationale de Recherche Biomédicale, Kinshasa, Democratic Republic of the Congo.
Melanie D OhiDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN 37232, USA.
Erica Ollmann SaphireDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA; Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA; The Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
George K LewisDivision of Vaccine Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Galit AlterRagon Institute of MGH, MIT, and Harvard, Cambridge, MA 02139, USA.
Andrew B WardDepartment of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.
Anne W RimoinDepartment of Epidemiology, Jonathan and Karin Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA 90095, USA.
Alexander BukreyevDepartment of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA; Galveston National Laboratory, Galveston, TX 77550, USA; Department of Microbiology & Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA. Electronic address: alexander.bukreyev@utmb.edu.
James E CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Chemical and Physical Biology Program, Vanderbilt University, Nashville, TN 37232, USA; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232, USA. Electronic address: james.crowe@vanderbilt.edu.
Vanderbilt University Medical Center · USVanderbilt University · USScripps Research Institute · USGalveston College · USIntegral Molecular (United States) · USUniversity of Maryland, Baltimore · USNational Institute of Biomedical Research · CDRagon Institute of MGH, MIT and Harvard · USUniversity of California, Los Angeles · USChildren's National · USThe University of Texas Medical Branch at Galveston · US
Funding
Regulatory Compliance Core - Galveston National Laboratory BSL4 OperationsUC7AI094660 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI Dennis A Bente · 2011 to 2026
$208.8MTumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MVanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MThe Vanderbilt Institute for Clinical and Translational Research (VICTR)UL1TR000445 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BERNARD, GORDON RAPHAEL · 2012 to 2016
$41.4MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MMechanistic Virology CoreU19AI109762 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI LAI, JONATHAN R. · 2014 to 2018
$29.6MSupplemental Research Project (SRP)U19AI109711 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GEISBERT, THOMAS WILLIAM · 2014 to 2018
$26.6MUniversity of California Launching Future Leaders in Global Health Research Training ProgramD43TW009343 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CRAIG R COHEN, Sung-Jae Lee · 2017 to 2026
$14.7MProject 3- Mucosal Determinants of Virus TransmissionP01AI124912 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LU, WUYUAN · 2016 to 2019
$14.4MEBOLA VIRAL GLYCOPROTEINS: STRUCTURAL ANALYSISR01AI067927 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI SAPHIRE, ERICA OLLMANN · 2006 to 2013
$3.6MIntegrated automated liquid handling system for novel antibody discoveryS10OD021737 · OD · VANDERBILT UNIVERSITY · PI CARNAHAN, ROBERT H · 2016 to 2016
$1.2MFIC NIH HHS D43 TW009343NCATS NIH HHS UL1 TR000445NCATS NIH HHS UL1 TR002243NCI NIH HHS P30 CA068485NCRR NIH HHS UL1 RR024975NIAID NIH HHS HHSN272201400058CNIAID NIH HHS P01 AI124912NIAID NIH HHS R01 AI067927NIAID NIH HHS U19 AI109711NIAID NIH HHS U19 AI109762NIAID NIH HHS UC7 AI094660NIDDK NIH HHS P30 DK058404NIH HHS S10 OD021737
Abstract
Ebolaviruses cause severe disease in humans, and identification of monoclonal antibodies (mAbs) that are effective against multiple ebolaviruses are important for therapeutics development. Here we describe a distinct class of broadly neutralizing human mAbs with protective capacity against three ebolaviruses infectious for humans: Ebola (EBOV), Sudan (SUDV), and Bundibugyo (BDBV) viruses. We isolated mAbs from human survivors of ebolavirus disease and identified a potent mAb, EBOV-520, which bound to an epitope in the glycoprotein (GP) base region. EBOV-520 efficiently neutralized EBOV, BDBV, and SUDV and also showed protective capacity in relevant animal models of these infections. EBOV-520 mediated protection principally by direct virus neutralization and exhibited multifunctional properties. This study identified a potent naturally occurring mAb and defined key features of the human antibody response that may contribute to broad protection. This multifunctional mAb and related clones are promising candidates for development as broadly protective pan-ebolavirus therapeutic molecules.
Indexed as
3T3 CellsAdultAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCell LineChlorocebus aethiopsCHO CellsCricetulusDisease Models, AnimalDrosophilaEbolavirusFemaleFerretsGlycoproteinsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralGlycoproteinsImmunoglobulin Gcross protectionEbola hemorrhagic feverebolavirusepitope mappingepitopesglycoproteinsheterologous immunitymonoclonal antibodiesneutralizing antibodiesviral antibodies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.